Alger Mid Cap 40 ETF underperformed its benchmark in Q1 2026 amid AI-sector recalibration. Read the full analysis for more ...
Perth biotech Syngenis is using artificial intelligence to slash the time and cost of discovering RNA therapies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results